Nuvalent, Inc. Class A (NUVL) Dividend History

Nuvalent, Inc. Class A (NUVL) is a biotechnology company focused on developing targeted therapies for genetically defined cancers. It aims to create precision medicines that address unmet medical needs by leveraging molecular insights and innovative drug discovery approaches.

One Broadway, 14th Floor, Cambridge, MA, 02142
Phone: 508-446-2272
Website: https://www.nuvalent.com

Dividend History

Nuvalent, Inc. Class A currently does not pay dividends

Company News

  • Nuvalent (NUVL) Q2 R&D Up 65%

    Nuvalent, a clinical-stage biotechnology company, reported a Q2 2025 net loss of $99.7 million while advancing its oncology pipeline, focusing on kinase mutation therapies for lung cancer. The company continues developing zidesamtinib and neladalkib, with potential drug launches anticipated in 2026.

    The Motley Fool
  • Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity

    Nuvalent presented positive data from its Phase 1/2 trials for zidesamtinib and NVL-655 at the ESMO Congress 2024. The company plans to initiate a Phase 3 trial for NVL-655 in the first half of 2025 and expects pivotal data from both trials in 2025. Nuvalent also announced a $350 million public offering.

    Benzinga
  • Why Earnings Season Could Be Great for Nuvalent (NUVL)

    Nuvalent (NUVL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Zacks Investment Research
  • Wall Street Breakfast: What Moved Markets

    Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.

    Seeking Alpha
    Featured Companies: BYSI CLEU COP CVX DECK ENSC EOG EQT INNV MRIN NKE OXY XOM
Page data last updated 09/07/2025 01:00:30 UTC